Archive ready
帝人株式会社の子会社設立に関するお知らせ
https://www.teijin.co.jp/news/2023/05/31/20230531_01.pdfMay 24, 2026 at 11:15 PM JST•The archive page, viewer, and downloads use this saved version.
May 24, 2026 at 11:15 PM JST·www.teijin.co.jp
The evidence pack includes HTML, screenshots, summaries, and metadata. It can be downloaded on Pro.
Saved PDF
帝人株式会社の子会社設立に関するお知らせ
StartedMay 24, 2026 at 11:15 PM JST
File size0.20 MB
SHA-256a5c2d17346397bbbef824898a8e89c0f9317207f6ebfb7f3854e962ec7d1d7ef
About this pageAI generated
This document announces that Teijin Limited has resolved to establish a new subsidiary, Teijin Regenet Co., Ltd., which will inherit the rights and obligations related to the regenerative medicine CDMO business, effective August 1, 2023. The new company will be a wholly-owned subsidiary of Teijin Limited, with a capital of 100 million yen, focusing on the regenerative medicine CDMO business. The purpose of this division is to enhance the flexibility of business strategies and promote future business development. There will be no changes to the name, location, representative, or capital of Teijin Limited after the division.